These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 23329684)
1. Rituximab as effective treatment in a case of severe subcutaneous nodulosis in rheumatoid arthritis. Sautner J; Rintelen B; Leeb BF Rheumatology (Oxford); 2013 Aug; 52(8):1535-7. PubMed ID: 23329684 [No Abstract] [Full Text] [Related]
3. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Tak PP; Rigby WF; Rubbert-Roth A; Peterfy CG; van Vollenhoven RF; Stohl W; Hessey E; Chen A; Tyrrell H; Shaw TM; Ann Rheum Dis; 2011 Jan; 70(1):39-46. PubMed ID: 20937671 [TBL] [Abstract][Full Text] [Related]
4. Rituximab infusion-related adverse event rates are lower in patients with systemic lupus erythematosus than in those with rheumatoid arthritis. Conti F; Ceccarelli F; Perricone C; Alessandri C; Conti V; Massaro L; Truglia S; Spinelli FR; Spadaro A; Valesini G Rheumatology (Oxford); 2011 Jun; 50(6):1148-52. PubMed ID: 21278072 [TBL] [Abstract][Full Text] [Related]
6. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate. Rigby W; Ferraccioli G; Greenwald M; Zazueta-Montiel B; Fleischmann R; Wassenberg S; Ogale S; Armstrong G; Jahreis A; Burke L; Mela C; Chen A Arthritis Care Res (Hoboken); 2011 May; 63(5):711-20. PubMed ID: 21557525 [TBL] [Abstract][Full Text] [Related]
7. Skin manifestations of rheumatoid arthritis: a study of 215 Turkish patients. Ergun T; Inanc N; Tuney D; Kotiloglu EK; Seckin D; Tetik C; Direskeneli H Int J Dermatol; 2008 Sep; 47(9):894-902. PubMed ID: 18937651 [TBL] [Abstract][Full Text] [Related]
8. Colchicine therapy for low-dose-methotrexate-induced accelerated nodulosis in a rheumatoid arthritis patient. Abraham Z; Rozenbaum M; Rosner I J Dermatol; 1999 Oct; 26(10):691-4. PubMed ID: 10554438 [TBL] [Abstract][Full Text] [Related]
9. Treatment of psoriasis with rituximab. Chang YS; Lee HT; Chen WS; Hsiao KH; Chen MH; Tsai CY; Chou CT J Am Acad Dermatol; 2012 May; 66(5):e184-5. PubMed ID: 22507592 [No Abstract] [Full Text] [Related]
10. Efficacy and safety of rituximab treatment in Indian pemphigus patients. Kanwar AJ; Tsuruta D; Vinay K; Koga H; Ishii N; Dainichi T; Hashimoto T J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):e17-23. PubMed ID: 22176540 [TBL] [Abstract][Full Text] [Related]
11. Depletion of B-cells with rituximab improves endothelial function and reduces inflammation among individuals with rheumatoid arthritis. Hsue PY; Scherzer R; Grunfeld C; Imboden J; Wu Y; Del Puerto G; Nitta E; Shigenaga J; Schnell Heringer A; Ganz P; Graf J J Am Heart Assoc; 2014 Oct; 3(5):e001267. PubMed ID: 25336464 [TBL] [Abstract][Full Text] [Related]
12. Subtherapeutic dosing of methotrexate in rheumatoid arthritis trials. Parker CT; Mewshaw E; Dennis GJ J Am Osteopath Assoc; 2004 Jan; 104(1):7-8. PubMed ID: 14992316 [No Abstract] [Full Text] [Related]
13. Effect of a single-cycle alternative dosing regimen for rituximab for recalcitrant pemphigus: a case series of 9 patients. Matsukura S; Knowles SR; Walsh S; Shear NH Arch Dermatol; 2012 Jun; 148(6):734-9. PubMed ID: 22351790 [TBL] [Abstract][Full Text] [Related]
14. Serum rituximab levels and efficiency of B cell depletion: differences between patients with rheumatoid arthritis and systemic lupus erythematosus. Reddy V; Croca S; Gerona D; De La Torre I; Isenberg D; McDonald V; Leandro M; Cambridge G Rheumatology (Oxford); 2013 May; 52(5):951-2. PubMed ID: 23424262 [No Abstract] [Full Text] [Related]
15. Predictive factors of rituximab response in rheumatoid arthritis: results from a French university hospital. Couderc M; Mathieu S; Pereira B; Glace B; Soubrier M Arthritis Care Res (Hoboken); 2013 Apr; 65(4):648-52. PubMed ID: 23045227 [TBL] [Abstract][Full Text] [Related]
18. Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritis. Vosslamber S; Raterman HG; van der Pouw Kraan TC; Schreurs MW; von Blomberg BM; Nurmohamed MT; Lems WF; Dijkmans BA; Voskuyl AE; Verweij CL Ann Rheum Dis; 2011 Jun; 70(6):1153-9. PubMed ID: 21444302 [TBL] [Abstract][Full Text] [Related]
19. Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment. Lal P; Su Z; Holweg CT; Silverman GJ; Schwartzman S; Kelman A; Read S; Spaniolo G; Monroe JG; Behrens TW; Townsend MJ Arthritis Rheum; 2011 Dec; 63(12):3681-91. PubMed ID: 22127691 [TBL] [Abstract][Full Text] [Related]
20. Pretreatment synovial transcriptional profile is associated with early and late clinical response in rheumatoid arthritis patients treated with rituximab. Hogan VE; Holweg CT; Choy DF; Kummerfeld SK; Hackney JA; Teng YK; Townsend MJ; van Laar JM Ann Rheum Dis; 2012 Nov; 71(11):1888-94. PubMed ID: 22736099 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]